<DOC>
	<DOCNO>NCT02808442</DOCNO>
	<brief_summary>This study aim evaluate safety ability UCART19 induce molecular remission pediatric patient relapse refractory CD19-positive B-cell acute lymphoblastic leukemia ( B-ALL ) ahead plan allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) .</brief_summary>
	<brief_title>Study UCART19 Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Patient relapse refractory CD19positive Bacute lymphoblastic leukaemia ( BALL ) 1. exhaust available treatment option 2. eligible alloHSCT suitable donor available Estimated life expectancy â‰¥ 12 week Considered medically fit alloHSCT Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Burkitt leukemia CD19negative Bcell leukemia Uncontrolled Central Nervous System ( CNS ) leukemia Active acute chronic GraftversusHost Disease ( GvHD )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>